WO2023214358 - FOXC1 EXPRESSION AS A COMPLEMENTARY DIAGNOSTIC ASSAY FOR PREDICTING EFFICACY OF ONCOLOGY DRUGS AND DRUG COMBINATION REGIMENS AND METHODS FOR USE
National phase entry:
Publication Number
WO/2023/214358
Publication Date
09.11.2023
International Application No.
PCT/IB2023/054671
International Filing Date
04.05.2023
Title **
[English]
FOXC1 EXPRESSION AS A COMPLEMENTARY DIAGNOSTIC ASSAY FOR PREDICTING EFFICACY OF ONCOLOGY DRUGS AND DRUG COMBINATION REGIMENS AND METHODS FOR USE
[French]
EXPRESSION DE FOXC1 EN TANT QUE DOSAGE DE DIAGNOSTIC COMPLÉMENTAIRE POUR PRÉDIRE L'EFFICACITÉ DE MÉDICAMENTS ONCOLOGIQUES ET DE RÉGIMES D'ASSOCIATION DE MÉDICAMENTS ET MÉTHODES D'UTILISATION
Applicants **
3N DIAGNOSTICS LTD.
Inventors
RAY, Partha S.
FAGNANI, Roberto
Priority Data
63/364,187
04.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5745 | |
| EPO | Filing, Examination, Granting | 88890 | |
| Japan | Filing, Examination, Granting | 4660 | |
| South Korea | Filing, Examination, Granting | 7022 | |
| USA | Filing, Examination, Granting | 23490 |
Total:
129,807
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Antibodies for determining the level of FOXC1 protein in a subject's tumor and methods of using FOXC1 antibodies to predict clinical efficacy of a cancer therapeutic, predict prognosis of a subject receiving the cancer therapeutic, and treat the subject based on the predictions of clinical efficacy and prognosis.[French]
L'invention concerne des anticorps permettant de déterminer le niveau de protéine FOXC1 dans la tumeur d'un sujet et des méthodes d'utilisation d'anticorps FOXC1 pour prédire l'efficacité clinique d'un agent thérapeutique anticancéreux, prédire le pronostic d'un sujet recevant l'agent thérapeutique anticancéreux et traiter le sujet sur la base des prédictions d'efficacité clinique et de pronostic.